Brief Summary
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting.
ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows:
* Metastatic colorectal cancer (CRC) – dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open.
* Recurrent/metastatic head and neck cancer (HNSCC) – dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open.
Protocol Interventions
Drug: Evorpacept (ALX148), Drug: Trastuzumab, Drug: Paclitaxel, Drug: Capecitabine, Drug: Eribulin, Drug: Gemcitabine, Drug: Vinorelbine